Home › Research › Down syndrome and Alzheimer's
Regional binding of tau and amyloid PET tracers in Down Syndrome autopsy brain tissue
Lemoine L, Ledreux A, Mufson EJ, Perez SE, Simic G, Doran E, Lott I, Carroll S et al.. Molecular neurodegeneration, 2020-10-23
Topic: Brain proteins, microglia and lab models
Plain-language summary
Abstract INTRODUCTION : Tau pathology is a major age-related event in Down syndrome with Alzheimer’s disease (DS-AD). Although recently, several different Tau PET tracers have been developed as biomarkers for AD, these tracers showed different binding properties in Alzheimer disease and other non-AD tauopathies. They have not been yet investigated in tissue obtained postmortem for DS-AD cases.
What this study adds
Evidence grade: Low
This study examined how two tau PET tracers and one amyloid ligand bind in post-mortem brain tissue from adults with Down syndrome and Alzheimer's disease. It assesses tracer binding properties for biomarker development and does not test any treatment, cure or prevention.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Lemoine, L., Ledreux, A., Mufson, E. J., Perez, S. E., Simic, G., Doran, E., et al. (2020). Regional binding of tau and amyloid PET tracers in Down Syndrome autopsy brain tissue. Molecular neurodegeneration. https://doi.org/10.21203/rs.3.rs-48040/v2
Vancouver
Lemoine L, Ledreux A, Mufson EJ, Perez SE, Simic G, Doran E, et al. Regional binding of tau and amyloid PET tracers in Down Syndrome autopsy brain tissue. Molecular neurodegeneration. 2020. doi:10.21203/rs.3.rs-48040/v2.
BibTeX
@article{lemoine2020-a970244c,
author = {Lemoine, L. and Ledreux, A. and Mufson, E. J. and Perez, S. E. and Simic, G. and Doran, E. and Lott, I. and Carroll, S. and others},
title = {{Regional binding of tau and amyloid PET tracers in Down Syndrome autopsy brain tissue}},
journal = {Molecular neurodegeneration},
year = {2020},
doi = {10.21203/rs.3.rs-48040/v2},
url = {https://doi.org/10.21203/rs.3.rs-48040/v2}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Although recently, several different Tau PET tracers have been developed as biomarkers for AD, these tracers showed different binding properties in Alzheimer disease and other non-AD tauopathies.
- They have not been yet investigated in tissue obtained postmortem for DS-AD cases.
- Here, we evaluated the binding characteristics of two Tau PET tracers ( 3 H-MK6240 and 3 H-THK5117) and one amyloid ( 3 H-PiB) ligand in the medial frontal gyrus (MFG) and hippocampus (HIPP) in tissue from adults with DS-AD and DS cases with mild cognitive impairment (MCI) compared to sporadic AD.
- METHODS : Tau and amyloid autoradiography were performed on paraffin-embedded sections.
Why it matters
This study examined how two tau PET tracers and one amyloid ligand bind in post-mortem brain tissue from adults with Down syndrome and Alzheimer's disease. It assesses tracer binding properties for biomarker development and does not test any treatment, cure or prevention.
Study details
- Evidence strengthLow
How this study scored 34/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 22 of the 64 points we could judge it on, which is 34 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Molecular neurodegeneration) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2020 — within 10 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 33222700) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 22 / 64 | Scored on 12 of 20 parts. We have no data for the rest, so they are left out: 22 of the 64 points we could judge it on is 34 out of 100. |
| Total | 34 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Down syndrome and Alzheimer's from nearby years
Also tagged “phosphorylated”
732 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 732 tagged studies.